Foley Partner Mark Waxman was quoted in an article titled “What impact will Obama administration have on human subjects research?” in the February 1, 2010 issue of IRB Advisor. Waxman discusses proposed changes to the health care industry under the Obama administration, stating that a possible change would be the lifting of the ban on federal funding of stem cell research and an increase in the number of stem cell trials. He adds that two bills to watch are the Fair Access to Clinical Trials act, which would strengthen a national data base of clinical trials information, and the Physician Payments Sunshine Act of 2008, which calls for transparency in physician relationships with pharmaceutical and device companies.
Related News
January 2, 2026
In the News
Nicholas O'Keefe on DExit Movement
Foley & Lardner LLP partner Nicholas O’Keefe examined whether there were lessons to be learnt from the Delaware Supreme Court’s recent decision reinstating Elon Musk’s performance award, in Agenda, a Financial Times publication.
January 2, 2026
In the News
Jason Mehta and Lauren Carboni Quoted on Major Health Care AI Cases
Foley & Lardner LLP partner Jason Mehta and senior counsel Lauren Carboni discuss significant upcoming health care AI cases in the Law360 article, “The High-Stakes Healthcare AI Battles To Watch In 2026."
January 2, 2026
In the News
Nicholas Ellis and Vanessa Miller Assess Transportation Policy Trends
Foley & Lardner LLP partners Nicholas Ellis and Vanessa Miller highlighted tariff transportation policy developments in the Law360 article, “Transportation Regulation, Legislation To Watch In 2026.”